Gilead Sciences
GILD
Performance
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and delivering medicines across virology, oncology, and inflammation to improve global health. The company emphasizes HIV, viral hepatitis, liver disease, cancer, and inflammatory conditions, with a pipeline spanning multiple therapeutic areas and a global presence. It highlights investments in research, patient access, and responsible corporate initiatives to advance health equity worldwide. Headquartered in Foster City, California, Gilead operates internationally to bring breakthrough therapies to patients around the world.
Recent News
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Re: The Power of the Markets: The Scandal that Keeps on Taking
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
FDA Sends Letters to 2,200 Sponsors, Demanding Public Trial Results
Flagship CEO Calls Out Attacks on Science, Warns of China Dominance
Gilead Price Target Raised to $175 From $171 at Morgan Stanley
FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Why Owning the Learning Loop Matters More Than Owning the Lab
Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.
CMS's Medicare Price Negotiations Start Round Three
Top Biotech Deals in March 2026
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
Salesforce’s New COO Leads AI‑Driven Turnaround, Internal Chart Shows
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Gilead Shows Belief in Its Partner’s Cancer Treatment with $7.8 Billion Buyout
CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations
STAT+: Gilead to Buy Cancer Biotech Tubulis for More than $3 Billion
Stock Movers: Gilead Sciences, Merck, Domino's (Podcast)
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
Gilead to Buy US Biotech Arcellx for up to US$7.8 Billion
Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Gilead to Acquire Germany's Tubulis for Up to $5 B, Boosting ADC Portfolio
Lynavoy (Linerixibat) Wins FDA Approval for Rare Liver Disease After Alfasigma-GSK Licensing Deal
HTGF: Where Public Mandate Meets Venture Discipline
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks
FDA Announces Evusheld Is Not Currently Authorized for Emergency Use in the U.S.
Pig Liver Xenotransplant Shows Promise, but More Work Remains
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
China Clears Its First Drug for Chronic Hepatitis D
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
ViiV Ownership Shifts as Pfizer Sells Its Stake
TSMC Posts 35% Jump in Q1 Revenue
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
More Data Support Investigational Drug Combo for HIV Therapy
STAT+: Pharmalittle: We’re Reading About FDA Backing Domestic Production, Another Gilead Deal, and More
Karyopharm’s Mixed Myelofibrosis Data; Rezolute to Seek FDA Approval Despite Trial Failure
